Sugi Predict

Sugi Predict / Compounds / SCHEMBL17488259

SCHEMBL17488259

SCHEMBL17488259

Nc1cc(Br)cc(Cl)c1N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.43
▸ CYP3A4 P08684 3/20 0.43
▸ GAA P10253 2/20 0.41
▸ CA1 P00915 3/20 0.39
▸ CA2 P00918 3/20 0.39
▸ CA9 Q16790 3/20 0.39
▸ NMT1 P30419 1/20 0.38
▸ TSHR P16473 4/20 0.33
▸ IDO1 P14902 1/20 0.33
▸ TDO2 P48775 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ CD44 P16070 1/20 0.33
▸ AHR P35869 3/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ PLAU P00749 1/20 0.31
▸ POLB P06746 1/20 0.31
▸ APEX1 P27695 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29674845 1.00 ALDH1A1 (0.43) ALDH1A1CYP3A4GAACA1CA2
SCHEMBL1004957 0.86 CYP3A4 (0.58) ALDH1A1CYP3A4GAACA1CA2
Hydrochloric Acid SCHEMBL8367686 0.83 CYP3A4 (0.55) ALDH1A1CYP3A4GAACA1CA2
SCHEMBL12819217 0.80 MAPT (0.40) ALDH1A1CYP3A4GAACA1CA2
SCHEMBL25313927 0.79 GAA (0.41) ALDH1A1CYP3A4GAACA1CA2
SCHEMBL30412179 0.79 GAA (0.41) ALDH1A1CYP3A4GAACA1CA2
SCHEMBL31424216 0.79 CA1 (0.54) ALDH1A1CYP3A4GAACA1CA2
SCHEMBL6217810 0.79 CA1 (0.54) ALDH1A1CYP3A4GAACA1CA2
SCHEMBL16728590 0.77 ALDH1A1 (0.44) ALDH1A1CYP3A4GAANMT1TSHR
SCHEMBL21225128 0.75 GAA (0.38) ALDH1A1CYP3A4GAANMT1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743078-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2026-05-20 — — EP disclosed
WO-2026090317-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2026-04-30 — — WO disclosed
US-12612412-B2 Antiviral heterocyclic compounds ENANTA PHARMACEUTICALS, INC. (US) 2026-04-28 — — US disclosed
WO-2025099451-A1 NEW COMPOUNDS AND METHODS Transition Bio Limited (GB) 2025-05-15 — — WO disclosed
WO-2025101780-A1 PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF OCTANT, INC. (US) 2025-05-15 — — WO disclosed
WO-2025015104-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2025-01-16 — — WO disclosed
WO-2024254990-A1 COMPOUND HAVING HETEROAROMATIC RING STRUCTURE, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 上海璎黎药业有限公司 2024-12-19 — — WO disclosed
EP-4067347-B1 HETEROCYCLIC INHIBITORS OF CBP/EP300 FOR THE TREATMENT OF CANCER GENENTECH INC (US) 2024-06-19 — — EP disclosed
EP-4352221-A1 MAP4K4 INHIBITORS AND METHODS OF SYNTHESIS AND USE THEREOF The Board Of Regents Of The University Of Oklahoma (US) 2024-04-17 — — EP disclosed
US-11945830-B2 Antiviral heterocyclic compounds ENANTA PHARMACEUTICALS, INC. (US) 2024-04-02 — — US disclosed
EP-3294729-A1 SUBSTITUTED QUINOXALINE DERIVATIVES SELVITA S.A. (PL) 2018-03-21 — — EP disclosed
EP-3294728-A1 SUBSTITUTED QUINOXALINE DERIVATIVES SELVITA S.A. (PL) 2018-03-21 — — EP disclosed
WO-2017205536-A2 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 — — WO disclosed
US-20170166563-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS INSTITUT PASTEUR KOREA (KR) 2017-06-15 — — US disclosed
US-20170166563-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS INSTITUT PASTEUR KOREA (KR) 2017-06-15 — — US disclosed
WO-2016180536-A1 SUBSTITUTED QUINOXALINE DERIVATIVES SELVITA S.A. (PL) 2016-11-17 — — WO disclosed
WO-2016180536-A1 SUBSTITUTED QUINOXALINE DERIVATIVES SELVITA S.A. (PL) 2016-11-17 — — WO disclosed
WO-2016180537-A1 SUBSTITUTED QUINOXALINE DERIVATIVES SELVITA S.A. (PL) 2016-11-17 — — WO disclosed
WO-2016180537-A1 SUBSTITUTED QUINOXALINE DERIVATIVES SELVITA S.A. (PL) 2016-11-17 — — WO disclosed
WO-2016016421-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS INSTITUT PASTEUR KOREA (KR) 2016-02-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612412-B2 Antiviral heterocyclic compounds ZC3HAV1, NHERF1, HM13 ALDH1A1 4093/4885CYP3A4 190/4885GAA 4300/4885
US-20170166563-A1 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS ALOX5, ALOX15, ALOX12 ALDH1A1 582/4885CYP3A4 261/4885GAA 4205/4885
US-11945830-B2 Antiviral heterocyclic compounds ACE, HPRT1, ACE2 ALDH1A1 2176/4885CYP3A4 147/4885GAA 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.